Bain Capital, Cinven's Lonza Specialty Ingredients deal cleared in EU
MLex Summary: Plans by private equity firms Bain Capital and Cinven to acquire joint control of Lonza Specialty Ingredients — the microbial control and chemicals business of Swiss healthcare giant Lonza — have been cleared by...To view the full article, register now.
Already a subscriber? Click here to view full article